Drugs / YA-101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06848231 | Mar 2025 → Jun 2026 overdue | multiple system atrophy | Dasher Neuroscience Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-04-14 | Dasher Neuroscience Inc. | Regulatory YA-101 Receives Orphan Drug Designation in Japan, Following U.S. FDA Fast Track, Advancing Global Development Plans dasherneuroscience.com ↗
YODA-KY (7829) announced today (23rd) that its new drug YA-101, following yesterday’s announcement of receiving Fast Track Designation from the US FDA, has been granted Orphan Drug Designation for the treatment of Multiple System Atrophy (MSA) by Japan’s Ministry of Health, Labour and Welfare (MHLW), marking a concrete step forward in the company’s global development strategy. |
| 2026-04-14 | Dasher Neuroscience Inc. | Regulatory YA-101 Granted Orphan Drug Designation by the EU EMA for the Treatment of Multiple System Atrophy dasherneuroscience.com ↗
YODA-KY (7829) announced today (14th) that it has received notification from the European Medicines Agency (EMA) that its investigational drug, YA-101, has been granted Orphan Drug Designation (ODD) for the treatment of Multiple System Atrophy. |
| 2026-04-14 | Dasher Neuroscience Inc. | Regulatory New Drug YA-101 Granted US FDA “Fast Track Designation” for the Treatment of Multiple System Atrophy dasherneuroscience.com ↗
YODA-KY (7829) announced today (22nd) that its subsidiary’s new drug YA-101 for the treatment of Multiple System Atrophy (MSA) has received Fast Track Designation from the U.S. Food and Drug Administration (FDA). |
All press releases naming this drug 4 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-07-29 | Dasher Neuroscience Inc. | Dasher Neuroscience Completes Patient Enrollment in Phase 2 Global Clinical Trial of Lead AI Drug Candidate YA-101 for Multiple System Atrophy (MSA) dasherneuroscience.com ↗ |
| 2026-04-14 | Dasher Neuroscience Inc. | YA-101 Receives Orphan Drug Designation in Japan, Following U.S. FDA Fast Track, Advancing Global Development Plans dasherneuroscience.com ↗ |
| 2026-04-14 | Dasher Neuroscience Inc. | YA-101 Granted Orphan Drug Designation by the EU EMA for the Treatment of Multiple System Atrophy dasherneuroscience.com ↗ |
| 2026-04-14 | Dasher Neuroscience Inc. | New Drug YA-101 Granted US FDA “Fast Track Designation” for the Treatment of Multiple System Atrophy dasherneuroscience.com ↗ |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | YA-101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06848231 ↗ |